Hepagam B Market Report 2026

Hepagam B Market Overview

• The Hepagam B market growth in the historic period has been driven by global hepatitis b prevalence, established role of immune globulins • Market expansion is supported by strengthening public health policies, rising healthcare worker safety measures • Growth Driver: Rising Hepatitis B Prevalence To Fuel Growth Of Market • Market Trend: Expansion Of Plasma Collection Centers To Strengthen Position In Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hepagam B Market?

HepaGam B is a human hepatitis B immune globulin used to prevent hepatitis B infection in individuals exposed to the virus, such as healthcare workers or newborns of infected mothers. It provides passive immunity by delivering antibodies against hepatitis B surface antigens. Typically, it is administered via injection and is part of post-exposure prophylaxis. The main types of hepagam B products are immunoglobulin preparations, vaccines, and antiviral therapies. Immunoglobulin preparations are plasma-derived products containing antibodies that provide passive immunity against specific infections. It is used for post-exposure prophylaxis and chronic hepatitis b treatment and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Hepagam B Market Growth Forecast?

The growth in the forecast period can be attributed to strengthening public health policies, rising healthcare worker safety measures, increased screening programs, growth in hospital based prophylaxis, global hepatitis elimination initiatives. Major trends in the forecast period include rising demand for post exposure prophylaxis, increased focus on maternal neonatal protection, expansion of immunoglobulin therapies, growing awareness of hepatitis b prevention, improved infection control protocols.

Global Hepagam B Market Segmentation

1) By Product Type: Immunoglobulin Preparations, Vaccines, Antiviral Therapies 2) By Indication: Post-Exposure Prophylaxis, Chronic Hepatitis B Treatment 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What Are The Drivers Of The Hepagam B Market?

The increasing prevalence of hepatitis B is expected to boost the growth of the hepagam B market going forward. Hepatitis B infections are liver infections caused by the hepatitis B virus (HBV), potentially leading to chronic disease, cirrhosis, or liver cancer. Hepatitis B infections are rising due to inadequate vaccination coverage, increased transmission in high-risk populations, and lack of awareness about preventive measures. HepaGam B is used to prevent hepatitis B infection by providing passive immunity in individuals exposed to the virus. For instance, in April 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, an estimated 254 million people worldwide were living with chronic hepatitis B infection in 2022, with 1.2 million new cases reported each year. The disease led to approximately 1.1 million deaths, primarily due to cirrhosis and hepatocellular carcinoma (primary liver cancer). Therefore, the increasing prevalence of Hepatitis B will drive the hepagam B industry. The increasing healthcare spending is expected to accelerate the growth of the hepagam B market. Healthcare spending is rising due to factors such as aging populations, increasing prevalence of chronic diseases, advancements in medical technology, and higher demand for quality care. Rising healthcare expenditure supports hepagam B by enabling greater investment in preventive treatments, improved access to immunoglobulin therapies, and better management of hepatitis B-related complications. For instance, in April 2024, according to the World Health Organization, a Switzerland-based government department, global health strategies aim to ensure that 80% of individuals living with chronic hepatitis B and C receive treatment by 2030. Therefore, the increasing healthcare spending will drive the growth of the hepagam B industry.

Key Players In The Global Hepagam B Market

Major companies operating in the hepagam b market are Kamada Ltd., Kibiopharma Inc., Emergent BioSolutions Inc.

Global Hepagam B Market Trends and Insights

The key trend in the hepagam B market is focusing on the expansion of plasma collection centers to gain a competitive edge in the industry. Plasma collection is the process of extracting plasma from a donor's blood, which is used for various medical treatments, including the production of immunoglobulins and clotting factor therapies. For instance, in September 2024, Kamada Limited, an Israel-based biopharmaceutical company, announced the opening of a new plasma collection center in Houston, Texas, aimed at enhancing its operations in specialty plasma collection. This 12,000 square foot facility is expected to support over 50 donor beds and achieve an annual collection capacity of approximately 50,000 liters. The center will focus on collecting both normal source plasma and specialty plasma, contributing an estimated $8 million to $10 million in annual revenue at full capacity. This expansion aligns with Kamada's strategy to become a leading global player in the specialty plasma-derived market.

Regional Insights

North America was the largest region in the hepagam B market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Hepagam B Market?

The hepagam B market consists of sales of hepatitis B vaccines, intravenous immunoglobulin, subcutaneous immunoglobulin, and hepatitis A immunoglobulin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hepagam B Market Report 2026?

The hepagam b market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hepagam b industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.